MR Vaccines Market, by Vaccine Brand (MR Vaccine and MRBEV (BE LTD.), by Distribution Channel (Private and Public), and by Region (Commonwealth of Independent States (CIS) Countries, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Sh

MR Vaccines Market, by Vaccine Brand (MR Vaccine and MRBEV (BE LTD.), by Distribution Channel (Private and Public), and by Region (Commonwealth of Independent States (CIS) Countries, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Measles and rubella is a live virus vaccine that protects against infection with the measles and rubella viruses. It works by causing the body to produce its antiviral defenses (antibodies). Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is a highly contagious infectious disease. Measles infection can result in significant complications such as pneumonia, ear infections, sinus infections, convulsions (seizures), brain damage, and death. Adults and children under the age of 5 years are at a higher risk of serious complications and mortality. When pregnant women contract rubella (also known as German measles), it can result in miscarriages, stillbirths, or birth abnormalities in their unborn children.
Market Dynamics
Measles and Rubella (MR) vaccine is a subcutaneous injection for active immunization against Measles and Rubella in young adults, adolescents, children, and infants at risk. Increasing incidence of Measles and Rubella (MR), ongoing clinical trials to develop MR vaccines, growing awareness about immunization services, rising government initiatives to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are the major factors that are expected to drive growth of the MR vaccines market over the forecast period.
For instance, according to the World Health Organization (WHO), from January 2021 to April 2021, eight African nations experienced major measles outbreaks that affected tens of thousands of children, owing to delayed vaccination programs or low routine immunization coverage.
Key features of the study:
This report provides an in-depth analysis of the MR vaccines market, and provides market size (US$ Mn. and No. of Doses in Mn.), and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the MR vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The MR vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MR vaccines market
Detailed Segmentation:
MR Vaccines Market, By Vaccine Brand:
MR Vaccine
MRBEV (BE LTD.)
MR Vaccines Market, By Distribution Channel:
Public
Private
MR Vaccines Market, By Region:
Commonwealth of Independent States (CIS) Countries
By Vaccine Brand
MR Vaccine
MRBEV (BE LTD.)
By Distribution Channel
Public
Private
By Country
Russia
Uzbekistan
Kazakhstan
Ukraine
Turkmenistan
Belarus
Armenia
Latin America
By Vaccine Brand
MR Vaccine
MRBEV (BE LTD.)
By Distribution Channel
Public
Private
By Country
Brazil
Mexico
Argentina
Honduras
Colombia
Peru
Chile
Europe
By Vaccine Brand
MR Vaccine
MRBEV (BE LTD.)
By Distribution Channel
Public
Private
By Country
Turkey
Asia Pacific
By Vaccine Brand
MR Vaccine
MRBEV (BE LTD.)
By Distribution Channel
Public
Private
By Country
Pakistan
Indonesia
Bangladesh
Philippines
Vietnam
Thailand
Myanmar
Malaysia
Cambodia
Nepal
Sri Lanka
Papua New Guinea
Mauritius
Middle East
By Vaccine Brand
MR Vaccine
MRBEV (BE LTD.)
By Distribution Channel
Public
Private
By Country
UAE
Israel
Iraq
Iran
Saudi Arabia
Jordan
Qatar
Oman
Syrian Arab Republic
Africa
By Vaccine Brand
MR Vaccine
MRBEV (BE LTD.)
By Distribution Channel
Public
Private
By Country/Region
Nigeria
Tanzania
Democratic Republic of Congo
Ethiopia
Kenya
South Africa
Egypt
Morocco
Ghana
Uganda
Burkina Faso
Angola
Algeria
Zimbabwe
Tunisia
Botswana
Libya
Namibia
Company Profiles
PT Bio Farma*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Bio-Manguinhos
BE Vaccines
Serum Institute of India
Crucell Switzerland AG
“*” marked represents similar segmentation in other categories in the respective section.